Drug Profile
Research programme: protein motion-based therapeutics - Relay Therapeutics
Latest Information Update: 30 Mar 2021
Price :
$50
*
At a glance
- Originator Relay Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer